Table 1 Characteristics of the included studies
Author | Country /ethnicity | CAVD diagnosis | Genotyping method | Study type | Case of RA (event/total) | Included cases | Control | ||
|---|---|---|---|---|---|---|---|---|---|
CUAVD | CBAVD | CUAVD | CBAVD | ||||||
Yang et al. (2015)24 | Chinese | CSC; excluding CF | Whole exon/flanking sequence | Case control | 1/6 | 1/11 | 5 | 10 | 50 NC |
Chiang et al. (2013)25 | Taiwanese | CSC; excluding CF and RA; | Whole exon/flanking sequence | Cross-sectional | 1/2 | 0/12 | 1 | 12 | NA |
Schwarzer and Schwarz (2012)13 | German | CSC; excluding CF and RA | Common variants screening | Cross-sectional | 5/13 | 5/110 | 8 | 105 | NA |
Sharma et al. (2009)26 | Indian | CSC; excluding CF and CFAS and RA | Whole exon/flanking sequence; 5T and TG test | Case control | 3/10 | 1/40 | 7 | 39 | 50 NC |
Radpour et al. (2007)27 | Iranian | CSC; excluding CF and RA | Whole exon/flanking sequence; 5T and TG test | Case control | NA | 0/112 | 7 | 112 | 84 NC |
Danziger et al. (2004)29 | U: Hispanic B: nine Asian or Asian-Indian, three Caucasian, and one Hispanic | CSC; excluding CF and RA | Common variants screening | Cross-sectional | 0/1 | 2/13 | 1 | 11 | 2 OA |
Grangeia et al. (2004)28 | Portuguese | CSC; excluding CF and RA | Whole exon/flanking sequence; 5T test | Case control | 0/4 | 3/34 | 4 | 31 | 114 NC; 16 OAZ and 23 NOAZ |
Kolettis and Sandlow (2002)31 | American | CSC; excluding CF and RA | Common variants screening | Cross-sectional | 4/11 | NA | 6 | NA | NA |
Robert et al. (2002)30 | French | CSC; excluding CF and RA | Common variants screening; 5T test | Cross-sectional | 1/7 | 2/40 | 6 | 38 | NA |
Attardo et al. (2001)33 | Italian | CSC; excluding CF and RA | Common variants screening; 5T test | Cross-sectional | 0/1 | 3/37 | 1 | 34 | NA |
Larriba et al. (2001)32 | Spanish | CSC; excluding CF | Whole exon/flanking sequence 5T test | Cross-sectional | NA | NA | 4 | 16 | 30 Non-CAVD |
Casals et al. (2000)14 | Spanish | CSC; excluding CF and RA | Whole exon/flanking sequence; 5T test | Case control | 10/24 | 6/110 | 14 | 104 | 200 NC |
Jézéquel et al. (2000)35 | French | CSC; excluding CF and CFAS; RAU | Whole exon/flanking sequence; 5T test | Cross-sectional | NA | NA | 3 | 37 | 7 OA |
Zeng et al. (2000)34 | Chinese | CSC | Common variants screening | Cross-sectional | NA | NA | 15 | NA | NA |
Castellani et al. (1999)36 | Italian | CSC; excluding CF and RA | Common variants screening; 5T test | Cross-sectional | 0/3 | 2/39 | 3 | 37 | NA |
Boucher et al. (1999)37 | French | CSC; excluding CF and RA | Common variants screening | Cross-sectional | 0/2 | 1/12 | 2 | 11 | 39 Non-CAVD; 37 oligozoospermia |
Dörk et al. (1997)38 | German with a few Austrian, Portuguese, Turkish, and Vietnamese | CSC; excluding CF and RA | Whole exon/flanking sequence; 5T test | Cross-sectional | 0/5 | 9/101 | 5 | 92 | NA |
Schlegel et al. (1996)16 | American | CSC; excluding CF and RA | Common variants screening | Cross-sectional | 5/19 | 6/53 | 12 | 52 | NA |
Casals et al. (1995)40 | Spanish | CSC; excluding CF | Common variants screening | Cross-sectional | NA | NA | 6 | 28 | NA |
Chillón et al. (1995)1 | European (Belgian, French, Spanish) and American | CSC; excluding CF and CFAS; RAU | Whole exon/flanking sequence; 5T test | Case control | NA | NA | 12 | 102 | 46 NC 10 non-CAVD |
Jarvi et al. (1995)39 | Canadian | CSC; excluding CF | Common variants screening; 5T test | Cross-sectional | NA | NA | 2 | 25 | 17 OAZ; 18 SF |
Mickle et al. (1995)7 | American | CSC; excluding CF and RA | Common variants screening | Cross-sectional | 5/21 | NA | 16 | NA | NA |
Culard et al. (1994)41 | French including one Turkish | CSC; excluding CF; RAU | Whole exon/flanking sequence | Cross-sectional | NA | NA | 1 | 8 | NA |
